Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial.
Journal: The Lancet. Infectious diseases
Published: October 15, 2025
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.
Journal: Viruses
Published: January 16, 2025
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 23, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
Journal: The Lancet. Infectious diseases
Published: June 12, 2023
Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
Journal: The New England journal of medicine
Published: December 14, 2022
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.
Journal: Cell reports
Published: September 29, 2022
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
Journal: AIDS (London, England)
Published: November 09, 2021
Association Between State Hepatitis A Vaccination Requirements and Hepatitis A Vaccination Rates.
Journal: Journal of the Pediatric Infectious Diseases Society
Published: September 02, 2021
Last Updated: 09/26/2026